Biol Psychiatry. 2007;doi:10.1016/j.biopsych.2006.11.023
Acute Selective Serotonin Reuptake Inhibitors Increase Conditioned Fear Expression: Blockade With a 5-HT2C Receptor Antagonist
Burghardt NS, Bush DEA, McEwen BS, LeDoux JE.
W.M. Keck Foundation Laboratory of Neurobiology Center for Neural Science, New York University, New York, Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology Rockefeller University, New York, New York
Background: Selective serotonin reuptake inhibitors (SSRIs) effectively treat various anxiety disorders, although symptoms of anxiety are often exacerbated during early stages of treatment. We previously reported that acute treatment with the SSRI citalopram enhances the acquisition of auditory fear conditioning, which is consistent with the initial anxiogenic effects reported clinically. Here, we extend our findings by assessing the effects of acute SSRI treatment on the expression of previously acquired conditioned fear.
Methods: Rats underwent fear conditioning drug-free. Tone-evoked fear responses were tested after drug treatment the following day. This protocol more closely resembles the clinical setting than pre-conditioning treatment, because it evaluates effects of treatment on a pre-existing fear rather than on the formation of a new fear memory.
Results: A single pre-testing injection of the SSRIs citalopram or fluoxetine significantly increased fear expression. There was no effect of the antidepressant tianeptine or the norepinephrine reuptake inhibitor tomoxetine, indicating that this effect is specific to SSRIs. The SSRI-induced enhancement in fear expression was not blocked by tropisetron, a 5-HT3 receptor antagonist, but was blocked by SB 242084, a specific 5-HT2C receptor antagonist.
Conclusions: Enhanced activation of 5-HT2C receptors might be a mechanism for the anxiogenic effects of SSRIs observed initially during treatment.
(Text has been reformatted for clarity; ed.)
Source...
Comment: There is a common conception that serotonin has some intrinsic 'feel good' quality. However, there is considerable evidence suggesting it has the opposite affect.
Serotonergic antidepressants increase serotonin levels both in synapses and the brain overall within an hour of the first dose, and levels may remain higher for some weeks. But they drop back to baseline or well below at about the time patients begin to feel an improvement in anxiety or depression.
1 And, as the authors of this study found (some for the second time
2), there is no initial increased anxiety with the French antidepressant
tianeptine (Stablon
®), a serotonin uptake enhancer. This suggests that tianeptine does directly what SSRIs do indirectly reduce brain serotonin levels/synthesis and that it is this reduction in serotonin that produces the therapeutic response. The fact that it begins working earlier than serotonin reuptake inhibiting antidepressants supports this hypothesis, though this is not the only possible explanation.
Additional support for the hypothesis comes from genetic rat models of depression. Rats with a high genetic predisposition for depression have up to 8 times more serotonin in their nucleus accumbens, prefrontal cortex, hippocampus, and hypothalamus than controls (there was no increase in other brain areas associated with anxiety & depression).
3 Chronic antidepressant treatment reduces the high serotonin levels to values found in the controls.
References:
(Note 5-HT = serotonin)- Bianchi M, Moser C, Lazzarini C, Vecchiato E, Crespi F. (2002)
Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.
Exp Brain Res. 2002 Mar;143(2):191-7. [Abstract]
Stenfors C, Yu H, Ross SB. (2001)
Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram.
Naunyn Schmiedebergs Arch Pharmacol, vol 363(2):p 222-32 [Abstract]
Alvarez JC, Sanceaume M, Advenier C, et al. (1999)
Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice.
Eur Neuropsychopharmacol, vol 10(1):p 31-6 [Abstract]
Moret C, Briley M.
Ex vivo inhibitory effect of the 5-HT uptake blocker citalopram on 5-HT synthesis.
J Neural Transm. 1997;104(2-3):147-60. [Abstract]
Trouvin JH, Gardier AM, Chanut E, et al. (1993)
Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat.
Life Sci, vol 52(18):p PL187-92 [Abstract]
Caccia S, Anelli M, Codegoni AM, Fracasso C, Garattini S. (1993)
The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain.
Br J Pharmacol. 1993 Sep;110(1):355-9. [Abstract]
Caccia S, Fracasso C, Garattini S, Guiso G, Sarati S. (1992)
Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain.
Neuropharmacology. 1992 Apr;31(4):343-7. [Abstract]
Leonard BE. (1988)
Pharmacological effects of serotonin reuptake inhibitors.
J Clin Psychiatry. 1988 Aug;49 Suppl:12-7. [Abstract]
- Burghardt NS, Sullivan GM, McEwen BS, et al. (2004)
The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine.
Biol Psychiatry. 2004 Jun 15;55(12):1171-8. [Abstract]
- Zangen A, Overstreet DH, Yadid G. (1997)
High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment.
J Neurochem, vol 69(6):p 2477-83 [Abstract]
tags: antidepressants ssris
links: digg this del.icio.us technorati reddit